← All candidates
12 insider filings on record.
22 filings on record.
CHRSCoherus Oncology, Inc.
NasdaqGM · Healthcare · $250.83M
$1.33
-6.99% · Sep 15
12 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · dailyNo open-market activity in range
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$250.83M
Float
132.5M
86% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
5.4
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
7 more transactions on Pro →Context
Wall St
$7.80 avg target
+486.5% vs today · 5 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 4 quarters beat
Q1 '26−$0.25 act+$0.02
Q4 '25−$0.34 act−$0.01
Q3 '25−$0.33 act−$0.04
Q2 '25−$0.34 act−$0.07
Coverage
What You Need To Know About The Coherus Oncology, Inc. (NASDAQ:CHRS) Analyst Downgrade TodaySimply Wall St. · 05-14Coherus Oncology, Inc. Q1 2026 Earnings Call SummaryMoby · 05-12Coherus Oncology Inc (CHRS) Q1 2026 Earnings Call Highlights: Strong LOQTORZI Sales Growth Amid ...GuruFocus.com · 05-12Coherus Oncology Q1 Earnings Call Highlights
The file stays open
22 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice